John Edwards
Hematology & Oncology · Indianapolis, INNPI 1487692794
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,045 of the $168,803 with a category attached, or 72.9%. Jazz Pharmaceuticals Inc. accounts for 74.1% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $49,835 and has fallen 99.9% since, to $49 in 2025. Among hematology & oncology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $700.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$125K
- Astellas Pharma US Inc$27K
- Incyte Corporation$4K
- F. Hoffmann-la Roche AG$4K
- Pfizer$4K
- Stemline Therapeutics Inc.$3K
- plus $3K from 26 others
Across 105 payments — averaging $7165.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$376K
- F. Hoffmann-la Roche AG$144K
- Incyte Corporation$75K
- Novartis$59K
- Merck$54K
- Jazz Pharmaceuticals Inc.$44K
What the payments were for
- Consulting fees$16,15710%
- Speaking & faculty fees$123,04573%
- Travel & lodging$22,36313%
- Food & beverage$7,1034%
- Education$1360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 110 | $125,077 |
| Astellas Pharma US Inc | 30 | $26,710 |
| Incyte Corporation | 13 | $4,003 |
| F. Hoffmann-la Roche AG | 2 | $3,700 |
| Pfizer | 2 | $3,519 |
| Stemline Therapeutics Inc. | 2 | $2,948 |
| E.r. Squibb & Sons, L.L.C. | 6 | $365 |
| Sanofi-aventis U.S. LLC | 5 | $325 |
| Bristol Myers Squibb | 13 | $294 |
| Amgen | 9 | $246 |
| Genmab U.S., Inc. | 4 | $182 |
| Morphosys, US Inc. | 6 | $153 |
| Adaptive Biotechnologies Corporation | 3 | $148 |
| GSK | 3 | $141 |
| TG Therapeutics, Inc. | 1 | $125 |
| AbbVie | 4 | $116 |
| Mallinckrodt Enterprises LLC | 1 | $111 |
| Tempus AI, Inc | 1 | $94 |
| Beigene USA, Inc. | 2 | $90 |
| Johnson & Johnson | 3 | $66 |
| Gilead | 3 | $54 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| Sanofi | 2 | $43 |
| ADC Therapeutics America, Inc. | 2 | $40 |
| Janssen Scientific Affairs, LLC | 1 | $31 |
| Seagen Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Agios Pharmaceuticals, Inc. | 2 | $28 |
| Acrotech Biopharma Inc. | 1 | $28 |
| Karyopharm Therapeutics Inc. | 2 | $27 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| CTI Biopharma Corp. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$168,803 in reported general payments places this provider in the 90th percentile of 224 hematology & oncology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 25 | $656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Acyclovir | $29 | $65625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Indianapolis
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
- Amro ElshouryIndianapolis$212K
- Brian MulherinIndianapolis$175K
- Muhammad Sarfraz NawazIndianapolis$172K
- Karam Al-IssaIndianapolis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.